A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, ...

During a live event, Naresh Bumma, MD, discussed CRS, oral and skin toxicities, and low discontinuation rates with ...

In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ...

Agency drug reviewers had questioned patient risk criteria and the efficacy endpoint used in a key trial supporting J&J's ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and ...

Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and progresses from precancerous to malignant states by tracing DNA ...

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only ...

Cambridge life science company CellCentric has raised $120 million Series C financing to advance its fight against an ...

Rising prevalence, aging populations, and therapeutic innovation are reshaping the landscape of multiple myeloma care and ...

As reported late last year, the AQUILA trial showed that treatment with daratumumab reduced the risk of progression to ...

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...